Boditech Med

• Selected by WHO ERPD to support global dengue response efforts
• Only FIA-based diagnostic products included, highlighting technological differentiation
• Enables accurate identification of both primary and secondary infections through combined antigen and antibody testing

Boditech Med, a global point-of-care diagnostics company, announced on the 27th that two of its dengue diagnostic kits have been selected by the World Health Organization (WHO) for inclusion in the Expert Review Panel for Diagnostics (ERPD).

Recently, WHO released an updated list of medicines and diagnostics for neglected tropical diseases (NTDs). As part of this effort, WHO activated the ERPD to identify high-performing diagnostic products suitable for urgent deployment in the fight against dengue.

Boditech Med’s selected products include:

▪ ichroma™ Dengue NS1 Ag (antigen detection)

▪ ichroma™ Dengue IgG/IgM (antibody detection)

Both are fluorescence immunoassay (FIA)-based point-of-care tests that meet WHO’s performance and quality standards. By combining antigen and antibody detection, they enable effective differentiation between primary and secondary dengue infections, which is clinically critical for early intervention and treatment decisions.

The ERPD serves as a fast-track assessment mechanism to evaluate high-performing in vitro diagnostic (IVD) products that have not yet undergone WHO Prequalification (PQ). Evaluation is conducted by an independent panel of experts, and selection is used as a key reference for procurement decisions by international agencies and national governments.

Out of submissions from around the world, only seven products were selected, with Boditech Med’s kits being the only FIA-based diagnostics on the list. The recommendation is valid for one year and is expected to facilitate international procurement and field deployment in dengue-endemic regions.

According to WHO, more than 14 million dengue cases were officially reported in 2024—over twice the number recorded in 2023. Latin America, particularly Brazil, accounts for over 70% of global cases, underscoring the urgent need for accurate and rapid diagnostics.

Eui-yeol Choi, CEO of Boditech Med, stated:

“Being selected by WHO’s ERPD validates our advanced technology and product reliability on a global level. As the only FIA-based product included, we are proud to offer high-quality diagnostic solutions that will contribute to global infectious disease control and early response efforts.”